{"id":560777,"date":"2026-02-02T11:12:22","date_gmt":"2026-02-02T11:12:22","guid":{"rendered":"https:\/\/www.europesays.com\/us\/560777\/"},"modified":"2026-02-02T11:12:22","modified_gmt":"2026-02-02T11:12:22","slug":"missing-link-between-parkinsons-protein-and-damage-to-brain-cells-discovered-sciencealert","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/560777\/","title":{"rendered":"Missing Link Between Parkinson’s Protein And Damage to Brain Cells Discovered : ScienceAlert"},"content":{"rendered":"

An investigation by researchers from Case Western Reserve University School of Medicine in the US has filled in a missing link between the toxic build-up of proteins in the neurodegenerative condition Parkinson’s<\/a> disease and the death of critical brain cells.<\/p>\n

The result of three years of research, the discovery connects alpha-synuclein proteins to a breakdown in mitochondrial function, both previously linked<\/a> to Parkinson’s.<\/p>\n

“We’ve uncovered a harmful interaction between proteins that damages the brain’s cellular powerhouses, called mitochondria,” says<\/a> neuroscientist Xin Qi.<\/p>\n

“More importantly, we’ve developed a targeted approach that can block this interaction and restore healthy brain cell function.”<\/p>\n

Related: ‘Zap-And-Freeze’ Brain Imaging Could Reveal The Secrets of Parkinson’s<\/a><\/strong><\/p>\n

Research has previously shown that toxic, abnormal clumps of alpha-synuclein damage neurons<\/a> in Parkinson’s. We also know that the disease is associated<\/a> with weaker mitochondria, depriving neurons of the energy they need to work effectively.<\/p>\n

Those two malfunctions have been linked before, but this new study provides a clearer idea of how.<\/p>\n

In lab tests, the team observed interactions between alpha-synuclein and an enzyme called ClpP<\/a>, which helps manage mitochondrial waste removal.<\/p>\n

\"CS2CS2 was shown to protect the ClpP enzyme. (Hu et al., Mol. Neurodegener., 2025)<\/p>\n

Their results suggest it is the way that alpha-synuclein binds to ClpP that disrupts mitochondria function, producing the knock-on effects so common in Parkinson’s \u2013 including a decline in dopamine production<\/a>.<\/p>\n

The most significant part of the research was the development of a potential treatment to counter this damaging biochemical reaction. A short length of protein called CS2 was designed to act as a decoy for alpha-synuclein, diverting its attention away from ClpP and cell mitochondria.<\/p>\n

In tests on human brain tissue, mouse models, and neurons developed in the lab, CS2 was shown to have positive effects. It reduced brain inflammation<\/a> and restored some motor and cognitive function in animals.<\/p>\n

“This represents a fundamentally new approach to treating Parkinson’s disease,” says<\/a> neurophysiologist Di Hu. “Instead of just treating the symptoms, we’re targeting one of the root causes of the disease itself.”<\/p>\n

\"Audition<\/a><\/p>\n

Researchers estimate it might be five years until human clinical trials<\/a> could evaluate CS2’s safety and efficiency in humans \u2013 this kind of biological tweaking can have unintended consequences that scientists will need to extensively test for.<\/p>\n

Nevertheless, it’s a promising step forward for Parkinson’s research<\/a>. Not only does the study identify one of the faults that is associated with the disease at the smallest molecular level, it also demonstrates a way it can potentially be repaired.<\/p>\n

All of this is in the context of what is already known about Parkinson’s. It’s a hugely complex disease where causes are difficult to differentiate from consequences \u2013 it’s likely that multiple treatment approaches<\/a> are going to be needed to finally find ways to cure the disease and stop it from developing in the first place.<\/p>\n

“One day we hope to develop mitochondria-targeted therapies that will enable people to regain normal function and quality of life, transforming Parkinson’s from a crippling, progressive condition into a manageable or resolved one,” says<\/a> Qi.<\/p>\n

The research has been published in Molecular Neurodegeneration<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"An investigation by researchers from Case Western Reserve University School of Medicine in the US has filled in…\n","protected":false},"author":3,"featured_media":560778,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[210,352,67,132,68],"class_list":{"0":"post-560777","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-health","9":"tag-msft-content","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116000741457910771","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/560777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=560777"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/560777\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/560778"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=560777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=560777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=560777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}